HLX04

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hepatocellular CarcinomaMetastatic Colorectal Cancer

251 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

1

HLX04

Shanghai Henlius Biotech

Phase 3

32

Ibrance

Pfizer

Preclinical

13

Viread

Gilead

Preclinical

14

Sovaldi

Gilead

Preclinical

15

Hepsera

Gilead

Preclinical

—6

Coreg

Akero Therapeutics

Preclinical

27

Doptelet

AAkarx

Preclinical

18

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

19

Vermox

WWim Janssens

Preclinical

110

Statin

Bristol-Myers Squibb

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting·Shanghai Henlius Biotech·Phase 2·NCT06349980·117 enrolled

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Unknown status·Shanghai Henlius Biotech·Phase 2·NCT05290220·60 enrolled

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Unknown status·Shanghai Henlius Biotech·Phase 2·NCT03973112·123 enrolled

First-line Treatment2 trials

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Completed·Shanghai Henlius Biotech·Phase 3·NCT03511963·677 enrolled

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Withdrawn·Shanghai Henlius Biotech·Phase 3·NCT04465734

Metastatic Colorectal Cancer1 trial

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Recruiting·Shanghai Henlius Biotech·Phase 2/3·NCT04547166·568 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Unknown status·Shanghai Henlius Biotech·Phase 1·NCT03757936·30 enrolled

Immunogenicity1 trial

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

Completed·Shanghai Henlius Biotech·Phase 1·NCT03483649·208 enrolled

Details

Drug Info

Related News